Indacaterol: a comprehensive review.

PubWeight™: 0.86‹?›

🔗 View Article (PMC 3728154)

Published in Int J Chron Obstruct Pulmon Dis on July 25, 2013

Authors

Andrea Rossi1, Guido Polese

Author Affiliations

1: Pulmonary Unit, Cardiovascular and Thoracic Department, University and General Hospital, Verona, Italy. andrea.rossi2@ospedaleuniverona.it

Articles cited by this

(truncated to the top 100)

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86

A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19

The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med (2004) 17.08

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J (2004) 16.84

Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07

Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med (1968) 7.13

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J (1995) 7.03

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med (1995) 6.99

Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med (2011) 6.56

A randomized study of endobronchial valves for advanced emphysema. N Engl J Med (2010) 6.23

Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med (2001) 5.76

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2007) 5.51

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet (2009) 5.51

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19

Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) 4.80

Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med (2002) 4.27

Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med (2011) 4.16

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med (2012) 3.51

Asthma and chronic obstructive pulmonary disease exhibit common origins in any country! Am J Respir Crit Care Med (2006) 3.47

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J (2004) 3.19

The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med (1978) 3.14

Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 2.83

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax (2010) 2.79

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med (2010) 2.56

How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol (2009) 2.46

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax (2012) 2.42

Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 2.09

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J (2010) 2.01

Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J (2010) 2.01

Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J (2004) 1.98

Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.97

Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review. Chest (2012) 1.92

Quality of life measurement for patients with diseases of the airways. Thorax (1991) 1.88

Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med (2010) 1.75

Pharmacology and therapeutics of bronchodilators. Pharmacol Rev (2012) 1.72

Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J (2005) 1.71

Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest (2006) 1.69

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J (2011) 1.66

Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med (2011) 1.61

Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest (2011) 1.46

Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med (2011) 1.41

QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax (2010) 1.36

Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis (2012) 1.35

Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis (2011) 1.35

The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med (2006) 1.34

Against the Dutch hypothesis: asthma and chronic obstructive pulmonary disease are distinct diseases. Am J Respir Crit Care Med (2006) 1.32

Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax (2003) 1.31

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med (2011) 1.31

Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J (2000) 1.30

Loss of alveolar attachments in smokers. A morphometric correlate of lung function impairment. Am Rev Respir Dis (1985) 1.30

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther (2010) 1.30

How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med (2012) 1.30

Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs (2005) 1.26

Therapeutic implications of the pathophysiology of COPD. Eur Respir J (2010) 1.26

The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J (2012) 1.23

Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest (2009) 1.21

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res (2010) 1.21

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med (2008) 1.21

Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res (2011) 1.19

Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD (2010) 1.19

In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest (1994) 1.19

Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis (2011) 1.19

24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin (2009) 1.15

Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J (1998) 1.13

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res (2010) 1.12

Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med (2011) 1.11

Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J (2009) 1.07

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther (2010) 1.07

Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther (2006) 1.06

COPD exacerbations . 3: Pathophysiology. Thorax (2006) 1.06

The risks and benefits of indacaterol--the FDA's review. N Engl J Med (2011) 1.06

Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. Int J Chron Obstruct Pulmon Dis (2011) 1.05

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med (2012) 1.04

Short term and long term effects of pulmonary rehabilitation on physical activity in COPD. Respir Med (2012) 1.03

Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD (2011) 1.01

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res (2011) 1.01

Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax (2008) 0.98

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis. Int J Chron Obstruct Pulmon Dis (2011) 0.97

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther (2011) 0.95

Rationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPD. COPD (2012) 0.95

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2012) 0.95

"Intrinsic" positive end-expiratory pressure in stable patients with chronic obstructive pulmonary disease. Eur Respir J (1990) 0.94

Dynamic hyperinflation is associated with a poor cardiovascular response to exercise in COPD patients. Respir Res (2011) 0.91

Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis (2010) 0.90

Intrinsic PEEP and the airbag effect. Respiration (2009) 0.90

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.89

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2012) 0.89

Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. COPD (2012) 0.88

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med (2012) 0.88

Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res (2012) 0.87

Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value Health (2012) 0.87

Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J (2011) 0.86

Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med (2010) 0.86

A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest (2011) 0.84

Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther (2009) 0.84

On-line monitoring of lung mechanics during spontaneous breathing: a physiological study. Respir Med (2010) 0.83

Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. Int J Chron Obstruct Pulmon Dis (2008) 0.81

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis (2012) 0.81

Indacaterol therapy in patients with COPD not receiving other maintenance treatment. Respir Med (2012) 0.79